Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Journal of Foot and Ankle Research 1/2011

Open Access 01-12-2011 | Oral presentation

Intra-articular hyaluronan (Synvisc®, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised, placebo controlled trial

Auteurs: Gerard V Zammit, Shannon E Munteanu, Hylton B Menz, Karl B Landorf, Christopher J Handley, Ayman ElZarka, Jason DeLuca

Gepubliceerd in: Journal of Foot and Ankle Research | bijlage 1/2011

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
insite
ZOEKEN

Background

The objective of this randomised controlled trial (RCT) was to comparatively assess the effectiveness of intra-articular hyaluronan (Synvisc®, hylan G-F 20) against an intra-articular sterile saline placebo for the treatment of radiographically confirmed, symptomatic first metatarsophalangeal joint (MTPJ) osteoarthritis (OA).

Methods

One hundred and fifty one (n=151) participants with symptomatic first MTPJ OA were randomly allocated to receive up to 1ml intra-articular injection of either Synvisc®, hylan G-F 20 or a sterile saline placebo. Outcomes were evaluated at 1, 3 and 6 months post-injection. Primary outcome measurements included the foot pain and foot function sub-scales of the Foot Health Status Questionnaire (FHSQ). Secondary outcome measurements were pain at the first MTPJ during walking and rest, self-reported stiffness at the first MTPJ, magnitude of symptom change with allocated treatment, global satisfaction, health-related quality of life (assessed via the Short-Form-36, version two), first MTPJ dorsiflexion range of motion, strength of the hallux plantarflexors, use of pain-relieving medication, concomitant therapies and dynamic plantar pressures.

Results

This RCT was completed in July 2010, with 147 (97%) participants followed up at 1 month, 127 (84%) at 3 months and 135 (89%) at 6 months. Both the placebo and treatment groups displayed improvements at the 1, 3, and 6 month follow-up periods. However, there were no statistically significant differences between the placebo or treatment groups for the primary outcome measures of FHSQ foot pain and foot function during any review period. With few exceptions, there were no statistically significant differences in the secondary outcome measurements between the groups.

Conclusions

A single intra-articular injection of Synvisc®, hylan G-F 20 is no more effective than a single intra-articular injection of sterile saline (placebo) in reducing symptoms and improving function in people with symptomatic, radiographically confirmed first MTPJ OA.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
Metagegevens
Titel
Intra-articular hyaluronan (Synvisc®, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised, placebo controlled trial
Auteurs
Gerard V Zammit
Shannon E Munteanu
Hylton B Menz
Karl B Landorf
Christopher J Handley
Ayman ElZarka
Jason DeLuca
Publicatiedatum
01-12-2011
Uitgeverij
BioMed Central
Gepubliceerd in
Journal of Foot and Ankle Research / Uitgave bijlage 1/2011
Elektronisch ISSN: 1757-1146
DOI
https://doi.org/10.1186/1757-1146-4-S1-O54